ReviewWorld journal of clinical oncology2018
Epitranscriptomics of cancer.
Review in World journal of clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Structural and mechanistic insights into the function of Leishmania ribosome lacking a single pseudouridine modification.Cell reports · 2024Article
- The role of RNA-modifying proteins in renal cell carcinoma.Cell death & disease · 2024Review
- Lytic Reactivation of the Kaposi's Sarcoma-Associated Herpesvirus (KSHV) Is Accompanied by Major Nucleolar Alterations.Viruses · 2022Article
- Role of main RNA modifications in cancer: NSignal transduction and targeted therapy · 2022Review
- Article
- Sperm Associated Antigens: Vigorous Influencers in Life.Cell journal · 2021Review
- RNA Modifications and Epigenetics in Modulation of Lung Cancer and Pulmonary Diseases.International journal of molecular sciences · 2021Review
- RNA editing affects cis-regulatory elements and predicts adverse cancer survival.Cancer medicine · 2021Article
- Platelets and tumor-associated RNA transfer.Blood · 2021Review
- Isolation of Cell-Free miRNA from Biological Fluids: Influencing Factors and Methods.Diagnostics (Basel, Switzerland) · 2021Review
- Evaluation of the Interplay between the ADAR Editome and Immunotherapy in Melanoma.Non-coding RNA · 2021Article
- RNA modifications and cancer.RNA biology · 2020Review
- Ribosome heterogeneity in stem cells and development.The Journal of cell biology · 2020Review
- Epigenetics of lung cancer: a translational perspective.Cellular oncology (Dordrecht, Netherlands) · 2019Review
- mJournal of translational medicine · 2019Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The functional impact of modifications of cellular RNAs, including mRNAs, miRNAs and lncRNAs, is a field of intense study. The role of such modifications in cancer has started to be elucidated. Diverse and sometimes opposite effects of RNA modifications have been reported. Some RNA modifications promote, while others decrease the growth and invasiveness of cancer. The present manuscript reviews the current knowledge on the potential impacts of N6-Methyladenosine, Pseudouridine, Inosine, 2'O-methylation or methylcytidine in cancer's RNA. It also highlights the remaining questions and provides hints on research avenues and potential therapeutic applications, whereby modulating dynamic RNA modifications may be a new method to treat cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.